English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

RuiYi In-Licenses Cancer/ Anti-Inflammatory mAb

Oct. 4, 2012

RuiYi, a drug discovery company based in San Diego and Shanghai, has obtained world-wide rights to an IL-6 mAb from ArGEN-X, a Dutch company. The molecule is being developed as a potential treatment for cancer and inflammatory diseases.